Answers are grounded in this paper and cite their sources.
Demonstrates the production of compound K in engineered bacteria, suggesting its potential for cosmetic use.
As a principal metabolite of ginsenosides, compound K (CK) exhibits remarkable antioxidant, anti-inflammatory, antidiabetic, and anticancer bioactivities. However, CK is naturally scarce in ginseng and its industrial application is limited by the lack of efficient deglycosylating enzymes for large-scale CK bioproduction. Here, we report a synthetic biology-driven approach for high-yield CK production via recombinant β-glycosidase-mediated bioconversion of the polar ginsenoside Rb1. The β‑glycosidase-encoding gene was introduced into Escherichia coli BL21 (DE3), and the resulting engineered strain produced 2.1 g/L β‑glycosidase in shake flasks and 10.1 g/L in a 5-L fermentor. The crude β-glycosidase exhibited excellent enzymatic activity; at a concentration of 1.5 g/L, it converted 95% of the Rb1 substrate (initial concentration 10 g/L) to CK within 4 h. In vitro studies demonstrated CK's high cytocompatibility and potent anti-aging effects, including suppression of reactive oxygen species (via upregulation of superoxide dismutase, catalase, and glutathione peroxidase), enhanced collagen I, Ⅲ and elastin synthesis, and matrix metalloproteinase-1 inhibition. These findings highlight CK as a promising candidate for anti-wrinkle formulations, supported by the feasibility of scalable bioproduction.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: